rs1641022

Variant summary

Our verdict is Benign. The variant received -18 ACMG points: 0P and 18B. BP4_ModerateBP6_Very_StrongBA1

The NM_020686.6(ABAT):​c.984C>A​(p.Val328Val) variant causes a synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.408 in 1,613,810 control chromosomes in the GnomAD database, including 138,819 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★).

Frequency

Genomes: 𝑓 0.33 ( 9839 hom., cov: 32)
Exomes 𝑓: 0.42 ( 128980 hom. )

Consequence

ABAT
NM_020686.6 synonymous

Scores

2

Clinical Significance

Benign criteria provided, multiple submitters, no conflicts B:5

Conservation

PhyloP100: 0.0640

Publications

18 publications found
Variant links:
Genes affected
ABAT (HGNC:23): (4-aminobutyrate aminotransferase) 4-aminobutyrate aminotransferase (ABAT) is responsible for catabolism of gamma-aminobutyric acid (GABA), an important, mostly inhibitory neurotransmitter in the central nervous system, into succinic semialdehyde. The active enzyme is a homodimer of 50-kD subunits complexed to pyridoxal-5-phosphate. The protein sequence is over 95% similar to the pig protein. GABA is estimated to be present in nearly one-third of human synapses. ABAT in liver and brain is controlled by 2 codominant alleles with a frequency in a Caucasian population of 0.56 and 0.44. The ABAT deficiency phenotype includes psychomotor retardation, hypotonia, hyperreflexia, lethargy, refractory seizures, and EEG abnormalities. Multiple alternatively spliced transcript variants encoding the same protein isoform have been found for this gene. [provided by RefSeq, Jul 2008]
ABAT Gene-Disease associations (from GenCC):
  • GABA aminotransaminase deficiency
    Inheritance: AR Classification: DEFINITIVE, STRONG, MODERATE, SUPPORTIVE, LIMITED Submitted by: Labcorp Genetics (formerly Invitae), Ambry Genetics, PanelApp Australia, Orphanet, G2P
  • genetic developmental and epileptic encephalopathy
    Inheritance: AR Classification: MODERATE Submitted by: ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -18 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.33).
BP6
Variant 16-8774919-C-A is Benign according to our data. Variant chr16-8774919-C-A is described in ClinVar as [Benign]. Clinvar id is 321082.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.422 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
ABATNM_020686.6 linkc.984C>A p.Val328Val synonymous_variant Exon 13 of 16 ENST00000268251.13 NP_065737.2 P80404X5D8S1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
ABATENST00000268251.13 linkc.984C>A p.Val328Val synonymous_variant Exon 13 of 16 1 NM_020686.6 ENSP00000268251.8 P80404

Frequencies

GnomAD3 genomes
AF:
0.332
AC:
50391
AN:
151928
Hom.:
9846
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.121
Gnomad AMI
AF:
0.341
Gnomad AMR
AF:
0.312
Gnomad ASJ
AF:
0.360
Gnomad EAS
AF:
0.398
Gnomad SAS
AF:
0.385
Gnomad FIN
AF:
0.513
Gnomad MID
AF:
0.361
Gnomad NFE
AF:
0.426
Gnomad OTH
AF:
0.338
GnomAD2 exomes
AF:
0.388
AC:
97623
AN:
251384
AF XY:
0.396
show subpopulations
Gnomad AFR exome
AF:
0.109
Gnomad AMR exome
AF:
0.331
Gnomad ASJ exome
AF:
0.361
Gnomad EAS exome
AF:
0.393
Gnomad FIN exome
AF:
0.496
Gnomad NFE exome
AF:
0.426
Gnomad OTH exome
AF:
0.379
GnomAD4 exome
AF:
0.416
AC:
608489
AN:
1461762
Hom.:
128980
Cov.:
63
AF XY:
0.416
AC XY:
302806
AN XY:
727162
show subpopulations
African (AFR)
AF:
0.103
AC:
3451
AN:
33478
American (AMR)
AF:
0.327
AC:
14630
AN:
44722
Ashkenazi Jewish (ASJ)
AF:
0.366
AC:
9556
AN:
26136
East Asian (EAS)
AF:
0.385
AC:
15276
AN:
39700
South Asian (SAS)
AF:
0.393
AC:
33916
AN:
86256
European-Finnish (FIN)
AF:
0.485
AC:
25908
AN:
53386
Middle Eastern (MID)
AF:
0.378
AC:
2170
AN:
5736
European-Non Finnish (NFE)
AF:
0.432
AC:
480238
AN:
1111956
Other (OTH)
AF:
0.387
AC:
23344
AN:
60392
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.480
Heterozygous variant carriers
0
21187
42374
63562
84749
105936
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Exome Hom
Variant carriers
0
14472
28944
43416
57888
72360
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.331
AC:
50383
AN:
152048
Hom.:
9839
Cov.:
32
AF XY:
0.337
AC XY:
25013
AN XY:
74316
show subpopulations
African (AFR)
AF:
0.120
AC:
5001
AN:
41516
American (AMR)
AF:
0.312
AC:
4772
AN:
15274
Ashkenazi Jewish (ASJ)
AF:
0.360
AC:
1249
AN:
3466
East Asian (EAS)
AF:
0.398
AC:
2052
AN:
5156
South Asian (SAS)
AF:
0.384
AC:
1850
AN:
4816
European-Finnish (FIN)
AF:
0.513
AC:
5417
AN:
10566
Middle Eastern (MID)
AF:
0.350
AC:
103
AN:
294
European-Non Finnish (NFE)
AF:
0.426
AC:
28926
AN:
67946
Other (OTH)
AF:
0.334
AC:
705
AN:
2110
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.498
Heterozygous variant carriers
0
1569
3139
4708
6278
7847
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
506
1012
1518
2024
2530
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.392
Hom.:
21245
Bravo
AF:
0.309
Asia WGS
AF:
0.348
AC:
1209
AN:
3478
EpiCase
AF:
0.427
EpiControl
AF:
0.427

ClinVar

Significance: Benign
Submissions summary: Benign:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

not provided Benign:3
-
Breakthrough Genomics, Breakthrough Genomics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:not provided

- -

Apr 20, 2017
Athena Diagnostics
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Feb 19, 2016
Mayo Clinic Laboratories, Mayo Clinic
Significance:Benign
Review Status:no assertion criteria provided
Collection Method:clinical testing

- -

Gamma-aminobutyric acid transaminase deficiency Benign:2
Feb 04, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Jan 13, 2018
Illumina Laboratory Services, Illumina
Significance:Benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.33
CADD
Benign
4.9
DANN
Benign
0.69
PhyloP100
0.064
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
2.7
Mutation Taster
=91/9
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.010
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs1641022; hg19: chr16-8868776; COSMIC: COSV51622298; API